nMARQ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Brief Description Of Study
Subjects with symptomatic PAF who have had at least one AF episode documented within one (1) year prior to enrollment and who have failed at least one antiarrhythmic drug (AAD). The Main Study will consist of a prospective, multi-center, randomized (1:1 concurrent nMARQ Catheter System [nMARQ] vs THERMOCOOL® Navigational Family of catheters [TC]), controlled, two-arm, single-blind design. Embedded within the Main Study will be a Subpopulation Neurological Assessment (SNA) with a prospective, controlled design, with consecutive enrollment.